Transfusion requirements and clinical outcome in intensive care patients receiving continuous renal replacement therapy: Comparison of prostacyclin vs. heparin prefilter administration

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 5, 2010, Pages 414-419

  Windeløv, Nis A ^a   Ostrowski, Sisse R ^a   Perner, Anders ^a   Johansson, Pär I ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Acute kidney failure; blood transfusion; critical illness; epoprostenol; hemorrhage; intensive care; mortality; renal replacement therapy

Indexed keywords

HEPARIN; PROSTACYCLIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; FEMALE; HUMAN; INTENSIVE CARE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD TRANSFUSION; COHORT STUDIES; EPOPROSTENOL; FEMALE; HEPARIN; HUMANS; INTENSIVE CARE; MALE; MIDDLE AGED; PLATELET AGGREGATION; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; THROMBOSIS; TREATMENT OUTCOME;

EID: 77954636160     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328338dc99     Document Type: Article

References (30)

1. Bunting S, Gryglewski R, Moncada S, Vane JR. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins 1976; 12:897-913.
2. Moncada S, Herman AG, Higgs EA, Vane JR. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the antithrombotic properties of vascular endothelium. Thromb Res 1977; 11:323-344.
3. Ubatuba FB, Moncada S, Vane JR. The effect of prostacyclin (PGT2) on platelet behaviour. Thrombus formation in vivo and bleeding time. Thromb Haemost 1979; 41:425-435.
4. Miller OV, Aiken JW, Hemker DP, Shebuski RJ, Gorman RR. Prostacyclin stimulation of dog arterial cyclic AMP levels. Prostaglandins 1979; 18:915-925.
5. Aiken JW, Gorman RR, Shebuski RJ. Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins 1979; 17:483-494.
6. Togna G, GAndolfi C, Andreoni A, Fumagalli A, Passarotti C, Faustini F, Patrono C. Inhibition of human platelet aggregation by stable analogs of prostacyclin. Pharmacol Res Commun 1977; 9:909-916.
7. Szczeklik A, Gryglewski RJ, Nizankowski R, Musial J, Pieton R, Mruk J. Circulatory and antiplatelet effects of intravenous prostacyclin in healthy men. Pharmacol Res Commun 1978; 10:545-556.
8. FDA. Prescribing information; 2008.
9. EMEA. Prescribing information; 2009.
10. Park MH. Advances in diagnosis and treatment in patients with pulmonary arterial hypertension. Catheter Cardiovasc Interv 2008; 71:205-213.
11. Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost 2006; 32 (Suppl 1):32-38.
12. Balik M, Waldauf P, Plasil P, Pachl J. Prostacyclin versus citrate in continuous haemodiafiltration: an observational study in patients with high risk of bleeding. Blood Purif 2005; 23:325-329.
13. Langenecker SA, Felfernig M, Werba A, Mueller CM, Chiari A, Zimpfer M. Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Crit Care Med 1994; 22:1774-1781.
14. Gainza FJ, Quintanilla N, Pijoan JI, Delgado S, Urbizu JM, Lampreabe I. Role of prostacyclin (epoprostenol) as anticoagulant in continuous renal replacement therapies: efficacy, security and cost analysis. J Nephrol 2006; 19:648-655.
15. Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 1994; 66:431-437.
16. Fiaccadori E, Maggiore U, Rotelli C, Minari M, Melfa L, Cappe G, Cabassi A. Continuous haemofiltration in acute renal failure with prostacyclin as the sole antihaemostatic agent. Intensive Care Med 2002; 28:586-593.
17. Kozek-Langenecker SA, Spiss CK, Gamsjager T, Domenig C, Zimpfer M. Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wien Klin Wochenschr 2002; 114:96-101.
18. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002; 288:1499-1507.
19. Hebert PC, Wells G, Tweeddale M, Martin C, Marshall J, Pham B, et al. Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group. Am J Respir Crit Care Med 1997; 155:1618-1623.
20. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409-417.
21. Abosaif NY, Tolba YA, Heap M, Russell J, El Nahas AM. The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability. Am J Kidney Dis 2005; 46:1038-1048.
22. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86:1327-1330.
23. Ghahramani N, Shadrou S, Hollenbeak C. A systematic review of continuous renal replacement therapy and intermittent haemodialysis in management of patients with acute renal failure. Nephrology (Carlton) 2008; 13:570-578.
24. Toft P, Gilsaa T. Acute renal failure in critically ill patients. Ugeskr Laeger 2007; 169:692-695.
25. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310.
26. Beirne C, Hynes N, Sultan S. Six years' experience with prostaglandin I2 infusion in elective open repair of abdominal aortic aneurysm: a parallel group observational study in a tertiary referral vascular center. Ann Vasc Surg 2008; 22:750-755.
27. Scheeren T, Susanto F, Reinauer H, Tarnow J, Radermacher P. Prostacyclin improves glucose utilization in patients with sepsis. J Crit Care 1994; 9:175-184.
28. Bihari DJ, Tinker J. The therapeutic value of vasodilator prostaglandins in multiple organ failure associated with sepsis. Intensive Care Med 1988; 15:2-7.
29. Zardi EM, Zardi DM, Cacciapaglia F, Dobrina A, Amoroso A, Picardi A, Afeltra A. Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs. Int Immunopharmacol 2005; 5:437-459.
30. Zardi EM, Zardi DM, Dobrina A, Afeltra A. Prostacyclin in sepsis: a systematic review. Prostaglandins Other Lipid Mediat 2007; 83:1-24.